Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 8/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL655255 | 0.83 | NR3C2 (0.47) | NR3C2MMP12NR3C1ALDH1A1KMT2A | |
| SCHEMBL21400859 | 0.79 | NR3C2 (0.47) | NR3C2MMP12NR3C1ALDH1A1KMT2A | |
| SCHEMBL2489889 | 0.79 | NR3C2 (0.50) | NR3C2MMP12NR3C1ALDH1A1KMT2A | |
| SCHEMBL592791 | 0.79 | NR3C2 (0.47) | NR3C2MMP12NR3C1ALDH1A1KMT2A | |
| SCHEMBL4343340 | 0.79 | NR3C2 (0.47) | NR3C2MMP12NR3C1ALDH1A1KMT2A | |
| SCHEMBL5367006 | 0.79 | NR3C2 (0.47) | NR3C2MMP12NR3C1ALDH1A1KMT2A | |
| SCHEMBL29712026 | 0.79 | NR3C2 (0.47) | NR3C2MMP12NR3C1ALDH1A1KMT2A | |
| SCHEMBL14476544 | 0.79 | NR3C2 (0.44) | NR3C2MMP12NR3C1ALDH1A1PARP1 | |
| SCHEMBL620088 | 0.77 | NR3C2 (0.45) | NR3C2MMP12NR3C1ALDH1A1KMT2A | |
| SCHEMBL12235340 | 0.76 | PARP1 (0.50) | NR3C2MMP12NR3C1PARP1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070772-A1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | Bugworks Research, Inc. | 2021-03-11 | — | — | US | disclosed |
| US-10912780-B2 | Heterocyclic compounds useful as anti-bacterial agents and method for production thereof | Bugworks Research, Inc. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200085834-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | Bugworks Research, Inc. | 2020-03-19 | — | — | US | disclosed |
| EP-2181996-A1 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2010-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200085834-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | UROD, ALPI, HLA-A | NR3C2 2682/4885MMP12 1264/4885NR3C1 4002/4885 |
| US-20210070772-A1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | HLA-B, BAX, REN | NR3C2 1247/4885MMP12 1300/4885NR3C1 2578/4885 |
| US-10912780-B2 | Heterocyclic compounds useful as anti-bacterial agents and method for production thereof | UROD, ALPI, HLA-A | NR3C2 2682/4885MMP12 1264/4885NR3C1 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.